Moli1901

AOP Orphan Pharmaceuticals AG · Phase 2 active Small molecule

At a glance

Generic name	Moli1901
Also known as	Lancovutide, 2622U90, duramycin
Sponsor	AOP Orphan Pharmaceuticals AG
Modality	Small molecule
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Lancovutide (Moli1901) Inhalation Solution Study in Adolescents and Adults With Cystic Fibrosis (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Moli1901 CI brief — competitive landscape report
Moli1901 updates RSS · CI watch RSS
AOP Orphan Pharmaceuticals AG portfolio CI